First-Line Therapy for Metastatic Pancreatic Cancer: A Case-Based Review of Current Evidence

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: July 15, 2015
Expiration Date: July 15, 2016

Expected time to complete this activity as designed: 30 minutes

There are no fees for participating in or receiving credit for this online activity.

Program Overview

Pancreatic cancer is an aggressive and deadly disease with an estimated 49,000 new cases and approximately 40,560 deaths in 2015. Although some progress has been made in the treatment of metastatic pancreatic cancer, median survival for patients with good functional status is still under one year. Thus, there is significant room for improvement.

Early detection is difficult, thus 80% of patients have locally advanced or distant metastases when diagnosed. Consequently, these patients need chemotherapy, radiotherapy, or palliative surgery to prolong their survival, control symptoms, and improve their quality of life.

This activity will explore the management of a 64-year-old female patient presenting with non-resectable metastatic pancreatic cancer. This case will explore appropriate combination regimens for frontline therapy for good performance status patients with metastatic pancreatic cancer examining new classes of treatments, new formulations of existing drugs, and potential emerging treatment options.

Target Audience

The target audience for this activity is oncologists and associated multidisciplinary clinical specialists who provide care to patients with pancreatic cancer.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Identify current first-line therapeutic options currently available following a diagnosis of advanced metastatic pancreatic cancer

  • Outline the current and evolving treatment landscape for metastatic pancreatic cancer, and identify how recent new advances in treatment options may be integrated into individualized patient management strategies


First-Line Therapy for Metastatic Pancreatic Cancer: A Case-Based Review of Current Evidence - Namrata Vijayvergia, MD, and Steven J. Cohen, MD

Instructions for Participation and Credit

This activity is eligible for credit through July 15, 2016. After this date, this activity will expire and no further credit will be awarded.
1. Read the target audience, learning objectives, and faculty disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biographies

Namrata Vijayvergia, MD
Chief Fellow
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Dr. Namrata Vijayvergia received her bachelor of medicine and bachelor of surgery (BMBS) from Jawaharlal Nehru Medical College of Rajasthan, Ajmer, India. She completed her internship, residency and chief residency at Temple University Hospital and her hematology/oncology fellowship at Fox Chase Cancer Center. She is chief fellow in hematology/oncology at Fox Chase Cancer Center in Philadelphia, Pennsylvania.

Dr. Vijayvergia holds American Board of Internal Medicine certification and is a member of the American Society of Clinical Oncology, American Society of Hematology, North American Neuroendocrine Tumor Society, American Medical Association, and the Italian Medical Association. Her research interest is in advanced solid and neuroendocrine tumors.

Steven J. Cohen, MD
Associate Professor
Department of Medical Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Dr. Steven Cohen received his medical degree from State University of New York at Stony Brook, New York. He was a resident in internal medicine at Temple University Hospital, Philadelphia, and a fellow/chief fellow in medical oncology and hematology at Fox Chase Cancer Center/Temple University Hospital. Dr. Cohen is an associate professor in the Department of Medical Oncology at Fox Chase Cancer Center. In addition he is program director, hematology/oncology fellowship, Temple University/Fox Chase Cancer Center; chief, GI medical oncology, co-leader, GI cancer service line, Fox Chase Cancer Center; and chief medical officer, Fox Chase Cancer Center Partners.

Dr. Cohen holds certification by the American Board of Internal Medicine and in medical oncology, and is a member of the American Society of Clinical Oncology and the Eastern Cooperative Oncology Group. He is a reviewer for Clinical Cancer Research, Journal of Clinical Oncology, Cancer, Clinical Colorectal Cancer, Clinical Advances in Hematology and Oncology, Expert Opinion on Drug Discovery, and Annals of Oncology, among others. Dr. Cohen has written numerous review articles, book chapters, and abstracts. His areas of interest include GI malignancies, colorectal cancer management, and pancreatic cancer.


MediCom WOrldwide, Inc. CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.5 contact hours of Continuing Education Credit. Universal Activity Number: 0827-0000-15-038-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.


As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures

Dr. Namrata Vijayvergia has disclosed no relevant financial relationships.

Dr. Steven Cohen has received honoraria related to formal advisory activities from Celgene Corporation.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, has no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

Off-Label Disclosures/Investigational Disclosures

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Dr. Vijayvergia and Dr. Cohen have indicated that they do not intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.

Dr. Vijayvergia has indicated that she does intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.

Dr. Cohen has indicated that he does not intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.

Hardware/Software/Internet Requirements

MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at

Provided by MediCom Worldwide, Inc.

This activity is supported by educational grants from Celgene Corporation and Aduro BioTech.

©2015 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Partners in Pancreatic Cancer would like to recognize and thank Celgene Corporation
for their educational support of

©2018 MediCom Worldwide, Inc. All rights reserved